MedTrace Logo

Communication Bridge 2

NCT03371706 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2024-10-17

Study results available
· View outcomes & findings →

Summary

This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech language therapy on communication abilities in individuals with PPA.

Participants with a diagnosis of PPA and their actively-engaged care partners will be involved in the study for 12 months. Each participant will receive a laptop equipped with the necessary applications and features for the study. Participants will receive 5 evaluations and 15 speech therapy sessions with a licensed speech therapist, as well as access to Communication Bridge, a personalized web application to practice home exercises that reinforce treatment strategies. There are no costs to participate in this study.

Conditions

  • Primary Progressive Aphasia

Interventions

BEHAVIORAL

Communication Bridge™

Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.

BEHAVIORAL

Evidence-Based Impairment Focused

Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Emily Rogalski, Ph.D. · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-03
Primary Completion
2023-03-23
Completion
2023-03-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03371706 on ClinicalTrials.gov